Earnings summaries and quarterly performance for Aveanna Healthcare Holdings.
Executive leadership at Aveanna Healthcare Holdings.
Board of directors at Aveanna Healthcare Holdings.
Research analysts who have asked questions during Aveanna Healthcare Holdings earnings calls.
Benjamin Hendrix
RBC Capital Markets
3 questions for AVAH
Also covers: ACHC, ADUS, AHCO +25 more
Benjamin Rossi
JPMorgan Chase & Co.
3 questions for AVAH
Also covers: AMED, ARDT, CON +7 more
Pito Chickering
Deutsche Bank
3 questions for AVAH
Also covers: ACHC, AHCO, BAX +18 more
Brian Tanquilut
Jefferies
2 questions for AVAH
Also covers: ACHC, ADUS, AHCO +29 more
Grayson McAllister
Truist Securities
2 questions for AVAH
Also covers: GRDN, RDNT
Meghan Holtz
Jefferies Financial Group Inc.
2 questions for AVAH
Also covers: AHCO, DGX, EHAB +4 more
Andrew Mok
Barclays
1 question for AVAH
Also covers: ACHC, ADUS, AGL +21 more
David Macdonald
Truist Securities
1 question for AVAH
Also covers: ENSG, GRDN, OPCH +3 more
Kieran Ryan
Deutsche Bank
1 question for AVAH
Also covers: AHCO, BTSG, DCGO +3 more
Michael Murray
RBC Capital Markets
1 question for AVAH
Also covers: ADUS, AHCO, AMED +7 more
Raj Kumar
Stephens
1 question for AVAH
Also covers: ACHC, ADUS, ARDT +7 more
Scott Fidel
Stephens Inc.
1 question for AVAH
Also covers: ACHC, ADUS, ALHC +17 more
Recent press releases and 8-K filings for AVAH.
Aveanna Provides Business Update and 2025 Guidance
AVAH
Guidance Update
Revenue Acceleration/Inflection
M&A
- Aveanna updated its 2025 guidance as of Q3, expecting revenue greater than $2.375 billion and Adjusted EBITDA greater than $300 million, following 11 consecutive quarters of beating and raising guidance. In Q3 2025, the company's revenue grew 22.2% year-over-year to $622 million, and consolidated Adjusted EBITDA increased 67.5% to $80.1 million.
- The company is executing a preferred payer strategy, with 93 agreements across its segments. It anticipates 56%-60% of its managed care Private Duty Services volumes will be under these contracts by year-end 2025, aiming for mid-60s% in 2026 and low-to-mid 80s% in 2-3 years.
- Aveanna projects a long-term organic growth rate of approximately 5%-7%. Strategic M&A, like the recent ThriveSkill Pediatrics acquisition , is expected to contribute to double-digit revenue growth in 2026 and 2027.
- As of Q3 2025, Aveanna reported strong liquidity of $478 million and generated $86.2 million in free cash flow. The company has reduced its net debt leverage to 4.6 times on an LTM basis, with a strategic goal to achieve sub-four times leverage.
Dec 9, 2025, 5:30 PM
Aveanna Healthcare Updates Strategic Plan and Financial Outlook
AVAH
Guidance Update
Revenue Acceleration/Inflection
M&A
- Aveanna Healthcare reported strong Q3 2025 revenues of $622 million, an increase of 22.2% year-over-year, and Adjusted EBITDA of $80.1 million, up 67.5% year-over-year. The company updated its 2025 guidance to expect revenue greater than $2.375 billion and Adjusted EBITDA greater than $300 million, marking its 11th consecutive quarter of beating and raising guidance.
- The company is executing a strategic plan focused on enhancing partnerships, cost efficiencies, and modernizing its Medical Solutions business, aiming for a long-term organic growth rate of 5%-7%. Aveanna expects double-digit revenue growth for 2026 and 2027, driven by volume and strategic M&A, such as the recent ThriveSkill Pediatrics acquisition.
- Aveanna is actively managing its capital structure, reporting over $478 million in liquidity and $86.2 million in free cash flow generated through Q3 2025. The company successfully refinanced its term loan facility, extending maturities to 2032 and reducing annual capital costs by $14 million, while also upsizing its revolving credit facility.
- The preferred payer strategy is gaining traction, with 93 agreements across its segments, and the company expects to align 56%-60% of its business with preferred payers by year-end 2025, targeting mid-60s% for 2026. In Q3 2025, Aveanna achieved its goal of 10 state rate increases.
Dec 9, 2025, 5:30 PM
Aveanna Healthcare Updates 2025 Guidance and Reports Strong Q3 2025 Performance
AVAH
Guidance Update
Revenue Acceleration/Inflection
M&A
- Aveanna Healthcare (AVAH) updated its 2025 guidance, expecting revenue greater than $2.375 billion and Adjusted EBITDA greater than $300 million. The company reported Q3 revenues of $622 million, up 22.2% year-over-year, and Q3 Adjusted EBITDA of $80.1 million, up 67.5% year-over-year. This marked the 11th consecutive quarter of beating and raising guidance.
- The company's strategic focus on preferred payer agreements and government affairs has led to 30 preferred payer agreements in Private Duty Services (PDS) as of Q3 2025, exceeding its goal, and 10 state rate increases. PDS, which accounts for approximately 82% of total revenue, is experiencing heightened growth.
- Aveanna aims for a long-term organic growth rate of approximately 5%-7%, with strategic tuck-in acquisitions potentially pushing annual revenue growth above 10%. The company anticipates double-digit revenue growth for 2026 and 2027, driven by volume and M&A.
- Aveanna reported $86.2 million in free cash flow generated through Q3 and strong liquidity of $478 million. Net debt leverage at the end of Q3 was 4.6 times, down three full turns in the first three quarters of the year, with a goal to be sub-four times levered. The company also refinanced its term loan facility, extending maturities to 2032 and reducing annual capital costs by about $14 million.
Dec 9, 2025, 5:30 PM
Aveanna Healthcare Holdings Inc. Reports Q3 2025 Financial Results and Provides 2025 Guidance
AVAH
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Aveanna Healthcare Holdings Inc. reported Q3 2025 revenue of $621.9 million, a 22.2% increase from Q3 2024, and Adjusted EBITDA of $80.1 million, a 67.5% increase year-over-year.
- For the full year 2025, the company provided guidance of over $2.375 billion in revenue and over $300 million in Adjusted EBITDA.
- Year-to-date 2025, the company generated $76.1 million in operating cash flow and $86.2 million in free cash flow.
- As of Q3 2025, Aveanna Healthcare Holdings Inc. had $478.7 million in total liquidity, including $145.9 million in cash.
Nov 7, 2025, 12:15 PM
Aveanna Reports Strong Q3 2025 Results and Raises Full-Year Outlook
AVAH
Earnings
Guidance Update
M&A
- Aveanna (AVAH) reported Q3 2025 revenue of approximately $622 million, a 22.2% increase over the prior year period, and adjusted EBITDA of $80.1 million, representing a 67.5% increase.
- The company raised its 2025 outlook, now anticipating revenue greater than $2.375 billion and adjusted EBITDA greater than $300 million.
- Strategic initiatives are progressing, with the number of Private Duty Services (PDS) preferred payer agreements increasing to 30, and 56% of total PDS MCO volumes now aligned with these partners. The integration of ThriveSkill Pediatrics is on target for completion by the end of 2025.
- Aveanna generated $86 million in free cash flow year-to-date and holds $146 million in cash on hand , with current net leverage at 4.62 times and an internal goal to achieve a "three-handle" in 2026 and 2027.
Nov 6, 2025, 3:00 PM
Aveanna Healthcare Holdings Announces Strong Q3 2025 Results and Raises Full Year Guidance
AVAH
Earnings
Guidance Update
Debt Issuance
- Aveanna Healthcare Holdings reported Q3 2025 revenue of $621.9 million, a 22.2% increase over the prior year period, and achieved net income of $14.1 million compared to a net loss in the prior year.
- Adjusted EBITDA for Q3 2025 was $80.1 million, representing a 67.5% increase compared to the prior year period.
- The company increased its Full Year 2025 revenue guidance to greater than $2.375 billion and Adjusted EBITDA guidance to greater than $300 million.
- On September 17, 2025, Aveanna completed a debt refinancing, which involved terminating its $415.0 million Second Lien Credit Agreement and expanding its revolving credit facility to $250.0 million.
Nov 6, 2025, 11:30 AM
Aveanna Healthcare Holdings Announces Third Quarter 2025 Financial Results and Revised 2025 Outlook
AVAH
Earnings
Guidance Update
Debt Issuance
- Aveanna Healthcare Holdings reported strong Q3 2025 results, with revenue of $621.9 million (up 22.2% year-over-year), net income of $14.1 million (compared to a net loss of $42.8 million in Q3 2024), and Adjusted EBITDA of $80.1 million (up 67.5%).
- The company increased its Full Year 2025 Revenue guidance to greater than $2.375 billion (from greater than $2.3 billion) and Adjusted EBITDA guidance to greater than $300 million (from greater than $270 million).
- Aveanna Healthcare Holdings completed a debt refinancing in Q3 2025, expanding its revolving credit facility to $250.0 million and extending maturity dates.
Nov 6, 2025, 11:30 AM
Aveanna Healthcare Holdings Announces Pricing of Secondary Offering
AVAH
- Aveanna Healthcare Holdings Inc. announced the pricing of a secondary offering of 10,000,000 shares of its common stock at a public offering price of $9.00 per share.
- The offering is being conducted by certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC.
- Aveanna Healthcare Holdings Inc. is not offering any shares and will not receive any proceeds from the sale of shares in this offering.
- The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares.
- The offering is expected to settle on October 23, 2025.
Oct 22, 2025, 1:50 AM
Aveanna Healthcare Holdings Announces Preliminary Third Quarter 2025 Financial Results
AVAH
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Aveanna Healthcare Holdings Inc. (AVAH) expects to report preliminary revenue of approximately $616 million to $624 million for the three-month period ended September 27, 2025.
- For the same period, preliminary net income is anticipated to be between $11 million and $15 million, and Adjusted EBITDA is expected to range from $77 million to $81 million.
- These preliminary Q3 2025 results indicate strong year-over-year growth, with revenue increasing by approximately 21.0% to 22.6%, net income by 125.7% to 135.0%, and Adjusted EBITDA by 61.0% to 69.3%.
Oct 21, 2025, 8:15 PM
Aveanna Healthcare Holdings Announces Preliminary Q3 2026 Financial Results
AVAH
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Aveanna Healthcare Holdings Inc. (AVAH) announced preliminary financial results for the three-month period ended September 27, 2025.
- The company expects to report revenue of approximately $616 million to $624 million, representing growth of approximately 21.0% to 22.6% over the prior year's third quarter.
- Net income is anticipated to be between $11 million and $15 million, reflecting growth of approximately 125.7% to 135.0% over the prior year's third quarter.
- Adjusted EBITDA is expected to be approximately $77 million to $81 million, an increase of approximately 61.0% to 69.3% from the prior year's third quarter.
- These financial results are preliminary estimates and are subject to the completion of financial closing procedures and potential adjustments.
Oct 21, 2025, 8:14 PM
Quarterly earnings call transcripts for Aveanna Healthcare Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more